170 related articles for article (PubMed ID: 20371707)
1. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models.
Bouyssou T; Casarosa P; Naline E; Pestel S; Konetzki I; Devillier P; Schnapp A
J Pharmacol Exp Ther; 2010 Jul; 334(1):53-62. PubMed ID: 20371707
[TBL] [Abstract][Full Text] [Related]
2. Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy.
Bouyssou T; Hoenke C; Rudolf K; Lustenberger P; Pestel S; Sieger P; Lotz R; Heine C; Büttner FH; Schnapp A; Konetzki I
Bioorg Med Chem Lett; 2010 Feb; 20(4):1410-4. PubMed ID: 20096576
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.
Battram C; Charlton SJ; Cuenoud B; Dowling MR; Fairhurst RA; Farr D; Fozard JR; Leighton-Davies JR; Lewis CA; McEvoy L; Turner RJ; Trifilieff A
J Pharmacol Exp Ther; 2006 May; 317(2):762-70. PubMed ID: 16434564
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.
Aparici M; Gómez-Angelats M; Vilella D; Otal R; Carcasona C; Viñals M; Ramos I; Gavaldà A; De Alba J; Gras J; Cortijo J; Morcillo E; Puig C; Ryder H; Beleta J; Miralpeix M
J Pharmacol Exp Ther; 2012 Aug; 342(2):497-509. PubMed ID: 22588259
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol.
Aparici M; Gavaldà A; Ramos I; Carcasona C; Otal R; Fernández-Blanco JA; Montero JL; García VM; López R; De Alba J; Doe C; Puig C; Vilella D; Miralpeix M
Eur J Pharmacol; 2016 Jan; 770():61-9. PubMed ID: 26656755
[TBL] [Abstract][Full Text] [Related]
6. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action.
Slack RJ; Barrett VJ; Morrison VS; Sturton RG; Emmons AJ; Ford AJ; Knowles RG
J Pharmacol Exp Ther; 2013 Jan; 344(1):218-30. PubMed ID: 23131596
[TBL] [Abstract][Full Text] [Related]
7. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol.
Casarosa P; Kollak I; Kiechle T; Ostermann A; Schnapp A; Kiesling R; Pieper M; Sieger P; Gantner F
J Pharmacol Exp Ther; 2011 Jun; 337(3):600-9. PubMed ID: 21357659
[TBL] [Abstract][Full Text] [Related]
8. Bronchoprotection by olodaterol is synergistically enhanced by tiotropium in a guinea pig model of allergic asthma.
Smit M; Zuidhof AB; Bos SI; Maarsingh H; Gosens R; Zaagsma J; Meurs H
J Pharmacol Exp Ther; 2014 Feb; 348(2):303-10. PubMed ID: 24307202
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of AZD9708, a novel, selective β2-adrenoceptor agonist with rapid onset and long duration of action.
Nicholls DJ; Jordan S; Cadogan E; Lawson M; Austin RP; Paine SW; Gardiner P; Bonnert R; Connolly S; Young A
Pulm Pharmacol Ther; 2012 Aug; 25(4):293-302. PubMed ID: 22659538
[TBL] [Abstract][Full Text] [Related]
10. The long-acting β2 -adrenoceptor agonist olodaterol attenuates pulmonary inflammation.
Wex E; Kollak I; Duechs MJ; Naline E; Wollin L; Devillier P
Br J Pharmacol; 2015 Jul; 172(14):3537-47. PubMed ID: 25824824
[TBL] [Abstract][Full Text] [Related]
11. Influence of receptor number on the stimulation by salmeterol of gene transcription in CHO-K1 cells transfected with the human beta2-adrenoceptor.
McDonnell J; Latif ML; Rees ES; Bevan NJ; Hill SJ
Br J Pharmacol; 1998 Oct; 125(4):717-26. PubMed ID: 9831907
[TBL] [Abstract][Full Text] [Related]
12. A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors.
Summerhill S; Stroud T; Nagendra R; Perros-Huguet C; Trevethick M
J Pharmacol Toxicol Methods; 2008; 58(3):189-97. PubMed ID: 18652905
[TBL] [Abstract][Full Text] [Related]
13. Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi.
Naline E; Trifilieff A; Fairhurst RA; Advenier C; Molimard M
Eur Respir J; 2007 Mar; 29(3):575-81. PubMed ID: 17135231
[TBL] [Abstract][Full Text] [Related]
14. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.
Gavaldà A; Miralpeix M; Ramos I; Otal R; Carreño C; Viñals M; Doménech T; Carcasona C; Reyes B; Vilella D; Gras J; Cortijo J; Morcillo E; Llenas J; Ryder H; Beleta J
J Pharmacol Exp Ther; 2009 Nov; 331(2):740-51. PubMed ID: 19710368
[TBL] [Abstract][Full Text] [Related]
15. The reassertion profiles of long acting β2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptor.
Patel S; Summerhill S; Stanley M; Perros-Huguet C; Trevethick MA
Pulm Pharmacol Ther; 2011 Apr; 24(2):247-55. PubMed ID: 21134482
[TBL] [Abstract][Full Text] [Related]
16. Desensitisation of mast cell beta2-adrenoceptor-mediated responses by salmeterol and formoterol.
Scola AM; Chong LK; Suvarna SK; Chess-Williams R; Peachell PT
Br J Pharmacol; 2004 Jan; 141(1):163-71. PubMed ID: 14662724
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent β
Yi C; Xing G; Wang S; Li X; Liu Y; Li J; Lin B; Woo AY; Zhang Y; Pan L; Cheng M
Bioorg Med Chem; 2020 Jan; 28(1):115178. PubMed ID: 31753798
[TBL] [Abstract][Full Text] [Related]
18. Olodaterol attenuates citric acid-induced cough in naïve and ovalbumin-sensitized and challenged guinea pigs.
Wex E; Bouyssou T
PLoS One; 2015; 10(3):e0119953. PubMed ID: 25781609
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices.
Sturton RG; Trifilieff A; Nicholson AG; Barnes PJ
J Pharmacol Exp Ther; 2008 Jan; 324(1):270-5. PubMed ID: 17916760
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties.
Hegde SS; Hughes AD; Chen Y; Steinfeld T; Jasper JR; Lee TW; McNamara A; Martin WJ; Pulido-Rios MT; Mammen M
J Pharmacol Exp Ther; 2014 Oct; 351(1):190-9. PubMed ID: 25100753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
